|
Apr 24
|
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
|
|
Apr 10
|
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR
|
|
Mar 14
|
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
|
|
Mar 12
|
Life Sciences Investor Forum Agenda Announced for March 13th
|
|
Feb 11
|
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch
|
|
Jan 2
|
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial
|
|
Dec 31
|
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement
|
|
Dec 31
|
Top Midday Decliners
|
|
Dec 31
|
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
|
|
Nov 19
|
COCP: Multiple Upcoming Catalysts…
|
|
Sep 26
|
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
|
|
Aug 19
|
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
|
|
Aug 19
|
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
|
|
Aug 14
|
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
|
Feb 20
|
COCP: Cocrystal Pharma provides updates on its clinical programs.
|
|
Jan 4
|
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
|
|
Dec 6
|
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
|
|
Nov 29
|
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
|
|
Nov 27
|
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
|
|
Nov 9
|
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
|